De Savi, Chris; Waterson, David; Pape, Andrew; Lamont, Scott; Hadley, Elma; Mills, Mark; Page, Ken M.; Bowyer, Jonathan; Maciewicz, Rose A. published the artcile< Hydantoin based inhibitors of MMP13-Discovery of AZD6605>, Application of C13H19BrN4O2, the main research area is piperidine ether aryl piperazine hydantoin inhibitor MMP13 osteoarthritis; Cyp P450; Hydantoin; Lead optimisation; MMP13; Zinc binder.
Piperidine ether and aryl piperazine hydantoins are reported as potent inhibitors of MMP13. A medicinal chem. campaign focused on replacing the reverse hydroxamate zinc binding group associated with historical inhibitors with a hydantoin zinc binding group then optimizing MMP13 potency, solubility and DMPK properties while maintaining good selectivity over MMP14. A number of high quality candidates were progressed and following rat and dog safety evaluation, AZD6605 (3m) was identified as a candidate drug.
Bioorganic & Medicinal Chemistry Letters published new progress about Enzyme inhibitors. 374930-88-8 belongs to class piperazines, and the molecular formula is C13H19BrN4O2, Application of C13H19BrN4O2.
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics